Proteomic changes upon treatment with semaglutide in individuals with obesity
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in participants with overweight or obesity, with or without diabetes: STEP 1 ( n = 1,311) and STEP 2 ( n = 645). We identified evidence supporting broad effects of semaglutide, implicating processes related to body weight regulation, glycemic control, lipid metabolism and inflammatory pathways. Several proteins were regulated with semaglutide, after accounting for changes in body weight and HbA 1c at end of trial, suggesting effects of semaglutide on the proteome beyond weight loss and glucose lowering. A comparison of semaglutide with real-world proteomic profiles revealed potential benefits on disease-specific proteomic signatures including the downregulation of specific proteins associated with cardiovascular disease risk, supporting its reported effects of lowering cardiovascular disease risk and potential drug repurposing opportunities. This study showcases the potential of proteomics data gathered from randomized trials for providing insights into disease mechanisms and drug repurposing opportunities. These data also highlight the unmet need for, and importance of, examining proteomic changes in response to weight loss pharmacotherapy in future trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Extended Data Fig. 2 Pathways implicated by proteins affected by semaglutide treatment in STEP 1 (a) and STEP 2 (b). The figure shows the effect of semaglutide treatment (according to SomaScan®) on hallmark gene sets. Circle sizes visually indicate the number of proteins in a set (log2-scale). Black diamonds within the coloured circles indicate sets that are significantly affected by treatment (false discovery rate-adjusted P value [q value] < 0.05). Enrichment P values were computed using CameraPR. Results for the full list of gene sets are available in Supplementary Tables 9 and 10 for STEP 1 and STEP 2, respectively. KRAS, Kirsten rat sarcoma virus; MTORC1, mammalian target of rapamycin complex 1; MYC, myelocytomatosis oncogene.](https://figures.cochat.ai/paper-figures/78524e5e90914fd492d3802451e7b81a/proteomic-changes-upon-treatment-with-semaglutide-in-individuals-with-obesity-figure-7.jpg)
![Extended Data Fig. 3 Proteins increased by semaglutide treatment are implicated in the exocrine pancreas. Effect size was normalized using the means and standard deviations at baseline to compare results across proteins, with positive and negative values indicating that semaglutide increased and decreased protein levels; −log10(P values) indicate the level of significance of the effect size (approximately 500 proteins [approximately 8–10% of the measured proteome] were significant). The red dashed line shows the Bonferroni correction limit, and the blue dashed line shows the false discovery rate. Effect sizes and P values were computed using linear regression. AMY2A/2B, alpha-amylase 2 A/2B; CLPS, caseinolytic protease subunit S; CPB1, carboxypeptidase B1; EOT, end of treatment; PNLIPRP1/2, pancreatic lipase-related protein 1/2; PNLIP, pancreatic lipase; PRSS1/2/3, trypsin 1/2/3.](https://figures.cochat.ai/paper-figures/897c46915b344e819afb65bbca9a1055/proteomic-changes-upon-treatment-with-semaglutide-in-individuals-with-obesity-figure-8.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Proteomic analyses from the STEP weight loss trials in people with or without T2D revealed semaglutide-induced changes in inflammatory and immune regulatory pathways that could not be fully attributed to metabolic improvements alone (25).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence from clinical trials suggests that GLP-1 medicines exert clinical benefits even in individuals who do not experience substantial weight loss (25).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Several GLP-1RAs, including semaglutide, have been shown to offer cardiovascular outcome benefit in people with T2D 33–35 .”
Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data
Burgess, S., Butterworth, A., & Thompson, S. G. (2013) · Genetic Epidemiology · doi:10.1002/gepi.21758 · Cited by 6,050
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 4×
“A total of 3,171 male and female participants were included in the STEP 1 and STEP 2 trials; please refer to the published papers for full details 20,21 .”
InfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 4×
“These benefits are now also evident in people with obesity at high CVD risk (or with known vascular disease) but without T2D, as shown by the favorable effects of semaglutide in the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) clinical trial 36 .”
InfluentialGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 1×
“Several GLP-1RAs, including semaglutide, have been shown to offer cardiovascular outcome benefit in people with T2D 33–35 .”
MINIMUM REDUNDANCY FEATURE SELECTION FROM MICROARRAY GENE EXPRESSION DATA
DING, C., & PENG, H. (2005) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720005001004 · Cited by 2,751
(2012) · Hepatogastroenterology · doi:10.5754/hge12458 · Cited by 1,977
Research works printed but not linked: 1
- camera: competitive gene set test accounting for inter-gene correlation (rdrr.io). PMC3458527 22638577
Cited by
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
Obesity, diabetes, and inflammation: Pathophysiology and clinical implications
Donath, M. Y., & Drucker, D. J. (2025) · Immunity · doi:10.1016/j.immuni.2025.09.011 · Cited by 70
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 83
“…therapy with either 2 mg exenatide once weekly in the EXSCEL trial 48 , or with 2.4 mg QW semaglutide in the STEP-1 and STEP-2 weight loss trials 49 , revealed reductions in circulating biomarkers of inflammation that also serve as indirect proxies for neuroinflammation in people with…”
InfluentialAdvances in GLP-1 receptor agonists for pain treatment and their future potential
He, Y., Xu, B., Zhang, M., Chen, D., Wu, S., Gao, J., Liu, Y., Zhang, Z., Kuang, J., & Fang, Q. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-01979-4 · Cited by 47
“In a recent 2025 study using large-scale proteomic analysis of serum samples from two phase 3 clinical trials, Maretty et al. demonstrated that semaglutide modulates the circulating proteome in individuals with overweight or obesity, with or without diabetes [67].”
InfluentialGlucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Giorgi, R. D., Ghenciulescu, A., Yotter, C. N., Taquet, M., & Koychev, I. G. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-335593 · Cited by 48
“20 From a mechanistic perspective, however, most evidence regarding the putative neuroprotective activity of GLP-1RAs stems from preclinical, that is, in vitro or animal models.”
InfluentialWestermeier, F., & Fisman, E. Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02608-9 · Cited by 45
“Interestingly, the proteomic changes induced by semaglutide in participants of the STEP trial were linked to a broad spectrum of biological processes, including body weight regulation, glycemic control, lipid metabolism, and inflammatory pathways [26].”
Gonzalez-Rellan, M. J., Riobello, C., Fang, S., da Silva, E. M., Koehler, J. A., Shang, R., Hammoud, R., Cao, X., Varela‐Rey, M., & Drucker, D. J. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.03.011 · Cited by 47
The expanding benefits of GLP-1 medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102214 · Cited by 42
“13 At least three complementary mechanisms of action contribute to the anti-inflammatory effects of GLP-1 medicines.”
The promise of GLP-1 receptor agonists for neurodegenerative diseases
Athauda, D. S., Greig, N. H., Meissner, W. G., Foltynie, T., & Gandhi, S. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194745 · Cited by 43
Qin, H., Yu, J., Yu, H., Zhou, C., Yuan, D., Wang, Z., Zhu, Z., Wei, G., Ou, P., Li, Z., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.01.008 · Cited by 32
Balancing weight and muscle loss in GLP1 receptor agonist therapy
Sanchis‐Gomar, F., Neeland, I. J., & Lavie, C. J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01160-6 · Cited by 25
“Proteomic data indicate systemic downregulation of anabolic signalling (such as the mTOR pathway) with GLP1 receptor agonist use 4 .”
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“More recently, deeper phenotyping in a controlled, randomized clinical trial setting has provided insights into mechanisms of GLP1 therapy in obesity and cardiovascular complications, including body weight-dependent and independent effects, and offers evidence of potential indication expansion 331 .”
Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents
Edvardsson, C. E., Adermark, L., Gottlieb, S., Alfreji, S., Emous, T. A., Gouda, Y., Thorsell, A., Vujičić, M., Aranäs, C., Benrick, A., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2025.106119 · Cited by 16
“98 These findings hint that GLP-1R-based therapeutics may engage epigenetic mechanisms, tentatively explaining their broad efficacy across multiple disorders.”
Optimizing Body Composition During Weight Loss: The Role of Amino Acid Supplementation
Cannavaro, D., Leva, F., Caturano, A., Berra, C., Bonfrate, L., & Conte, C. (2025) · Nutrients · doi:10.3390/nu17122000 · Cited by 15
GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies
Luo, Y., Xu, H., Zhao, Y., Yang, B., & Zhang, Y. (2025) · Food & Function · doi:10.1039/d5fo03273c · Cited by 12
Human Plasma Proteomics Links Modifiable Lifestyle Exposome to Disease RiskPreprint
Isaac, S., Ellis, R. J., Jee, Y. H., Murthy, V. L., Udler, M. S., Neale, B. M., Sunyaev, S., Gusev, A., Martin, A. R., & Patel, C. J. (2025) · medRxiv · doi:10.1101/2025.05.07.25327178 · Cited by 12
Kang, S., Baker, S. A., Hayhoe, B. W. J., Price, G. J., Novak, G., Wong, J., Middleton, L. T., & Robinson, O. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100274 · Cited by 10
“Plasma-based, high-throughput proteomic assays, including the Olink and aptamer-based Somalogic platforms, have emerged as powerful tools for predicting common diseases across diverse populations [6,7].”
Ábel, T., & Csajbókné, É. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031186 · Cited by 12
“It has been shown to prevent excessive fission and support fusion (e.g., maintaining optic atrophy 1/mitofusins2 (OPA1/Mfn2) levels) under metabolic stress [57].”
InfluentialBiological aging clocks in health and disease
Wyss‐Coray, T., & Topol, E. J. (2026) · Nature Medicine · doi:10.1038/s41591-026-04495-3 · Cited by 18
“The GLP-1 drug class has been associated with slowing the aging process according to epigenetic, proteomic and transcriptomic clocks in rodents, epigenetic clocks in people with obesity or diabetes, and by favorable proteomic profiles from randomized clinical trials 123,127,128 .”
Kho, P. F., Wary, N. K., Zanetti, D., Abbasi, F., Knowles, J. W., Panyard, D. J., Watson, K. T., Stell, L., Lazzeroni, L. C., Gustafsson, S., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2025.156263 · Cited by 7
Singh, B., Karpov, O. A., & Mayr, M. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120637 · Cited by 8
Nanomaterials for the treatment and monitoring of obesity: Targeting adipose tissue macrophages
Tang, Y., Chen, O., Dong, B., Liu, L., Ying, W., & Liu, H. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.09.052 · Cited by 10
Decoding the hallmarks of GLP-1RA weight-loss super-responders
Venkatakrishnan, A., Murugadoss, K., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag021 · Cited by 8
Byun, S., Sotzen, M. R., Knappenberger, M. A., Bento, M. T., Asker, M., Olekanma, D. I., & Skibicka, K. P. (2025) · Comprehensive physiology · doi:10.1002/cph4.70083 · Cited by 8
“Previous studies have reported that GLP-1RAs exert anti-inflammatory effects both systemically and within adipose tissues (Maretty et al. 2025; Mehdi et al. 2023; Lee et al. 2012; Wong et al. 2024).”
The critical role of inflammation in atherosclerotic coronary artery heart disease
Spindler, J. S., & Henning, R. J. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103261 · Cited by 8
Circular RNAs in metabolic health: bridging the gap between molecular biology and therapy
Huang, Y., He, T., Zheng, J., Chen, J., & Yang, Z. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08450-5 · Cited by 5
“Furthermore, circRNAs may also be employed in protein replacement therapies, such as expressing speci fi c proteins to treat rare diseases[164 – 167].”
Chronic kidney disease, complex conditions, and advancing therapeutics: new hope and challenges
Lees, J. S., Škoberne, A., Zhang, L., Wyatt, C., Fabian, J., Wang, A. Y.-M., Oni, L., & Levin, A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00653-7 · Cited by 6
Tang, H., Donahoo, W. T., DeKosky, S. T., Lee, Y. A., Kotecha, P., Svensson, M., Bian, J., & Guo, J. S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70313 · Cited by 5
Inhibition of Tumor Lipogenesis and Growth by Peptide‐Based Targeting of SREBP Activation
Luo, S., Huang, Y., Jiang, X., Wang, Z., He, X., Meng, Y., Li, S., Li, M., Xu, D., Mao, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202508111 · Cited by 9
OMG! A proteomic determinant of neurodegenerative resiliency
Duggan, M. R., Oh, H. S., Frank, P., Gómez, G., Zweibaum, D. A., Cui, Y., Chen, J., Surapaneni, A., Blew, C., Dark, H. E., et al. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00921-1 · Cited by 5
“As evidenced by recent clinical trials, glucagon-like peptide-1 (GLP-1) analog treatment can increase OMG levels, whereas dietary intervention alone cannot [50, 51].”
Stefanakis, K., de Piñeres, V. G., Veeragandham, P., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156493 · Cited by 6
Advancing precision health discovery in a genetically diverse health system
Haas, R., Margolis, M. P., Wei, A., Yamaguchi, T. N., Feng, J. A., Tran, T., Tozzo, V., Queen, K. J., Mootor, M. F. E., Patil, V., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.007 · Cited by 8
Proteomic aging clocks in epidemiological studies: advances, applications and prospects
Xiao, H., Lau, C. E., Dehghan, A., & Robinson, O. (2026) · Nature Aging · doi:10.1038/s43587-026-01118-x · Cited by 6
“…semaglutide obesity trials revealed hundreds of treatment-responsive plasma proteins and demonstrated a significant reduction in a protein-based cardiovascular risk score versus placebo, underscoring the ability of proteomic measures to detect clinically meaningful changes beyond weight loss 128 .”
The Evolution of Primary Aldosteronism and the Role of NorrinPreprint
Salle, S. P., Heydarpour, M., Tsai, C., Brown, J. M., Newman, A. J., Mahrokhian, S., Hanna, I., Honzel, B., Tsai, L. C., Waikar, S. S., et al. (2025) · medRxiv · doi:10.1101/2025.06.05.25329066 · Cited by 5
Corley, M. J., Dwaraka, V. B., Pang, A. P. S., Labbato, D. E., Smith, R. S., Eckard, A. R., & McComsey, G. A. (2025) · medRxiv · doi:10.1101/2025.07.09.25331038 · Cited by 4
“…agents originally developed for metabolic indications, such as glucagon-like peptide-1 (GLP-1) receptor agonists(Wilding et al. 2021; Davies et al. 2021; Marso et al. 2016; Maretty et al. 2025), have garnered attention due to their potential dual roles in metabolic regulation and aging biology.”
Zafar, M., Albrahimi, A. A., Alanezi, N. M. S., SayedAlameen, A. A., Alshammari, L. H., Alsuwayt, F. N. H., Alshammari, W. M., & Faiyaz, S. S. M. (2025) · Journal of Education and Health Promotion · doi:10.4103/jehp.jehp_24_25 · Cited by 4
“[23,24] 29.20% Attitudinal analysis revealed that affordability was a key determinant for 54% of participants, and a majority (83.8”
InfluentialNewer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Global status and trends of proteomics in obesity: a bibliometric analysis and knowledge graph study
Wu, X., Chen, Y., Wu, T., Pan, Q., & Guo, L. (2025) · Tropical Medicine and Health · doi:10.1186/s41182-025-00785-7 · Cited by 4
“The proteomic analyses have helped identify key protein markers associated with inflammation, glucose con-trol, and lipid dysregulation [21–23].”
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects
Chadwick, J., Berry, C., Carpenter, M. A., Gulati, G., Heck, S. L., Hinterberg, M., Holman, R. R., Lee, M. M. Y., Omland, T., Paterson, C., et al. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70077 · Cited by 3
Incretin Signaling Neighborhoods and Adverse Drug Reactions
Wright, S. C., Lindquist, P., ROSENKILDE, M. M., & Lauschke, V. M. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-062124-015046 · Cited by 3
Observation of unique stable nano-assemblies of a lipidated glucagon-like peptide 1 analogue
Brichtova, E. P., dos Santos, A. L. G., & Jackson, S. (2025) · Soft Matter · doi:10.1039/d5sm00801h · Cited by 2
Semaglutide in MASH with F2-F3 fibrosis: a holistic perspective on the ESSENCE phase 3 trial
Pirola, C. J., & Sookoian, S. C. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.13 · Cited by 3
Repetti, G. G., Abel, E. D., Tontonoz, P., & Sallam, T. (2026) · Circulation Research · doi:10.1161/circresaha.126.328680 · Cited by 3
Proteomic signatures as biomarkers of atherosclerosis burden
Zhang, L., Omarov, M., Xu, L., Das, B., Luo, H., Hauck, S. M., Petrera, A., Yu, Z., Goonewardena, S. N., Zeggini, E., et al. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag140 · Cited by 3
Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial
Colhoun, H. M., Lincoff, A. M., Ryan, D. H., Lingvay, I., Kahn, S. E., Hovingh, G. K., Hardt‐Lindberg, S., Oral, T. K., Weeke, P. E., Linder, M., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag524 · Cited by 7
Glucagon-like peptide-1 receptor agonists in neuropathic pain: hype or hope?
Choi, J. I. (2025) · The Korean journal of pain · doi:10.3344/kjp.25214 · Cited by 2
“This study reported attenuated alterations in the expression of proteins typically associated with neuropathic pain pathophysiology [18].”
Obesity-Associated Chronic Inflammation: A Protective Mechanism against Type 2 Diabetes
Ye, J. (2025) · Immune discovery. · doi:10.70322/immune.2025.10007 · Cited by 1
The Plasma Free Fatty Acid Carrier Proteome is Altered in Diet‐Induced and Genetically Obese Mice
Tomoo, K., Zhang, Y., Portalatin, A. Z. D., & Henderson, G. C. (2026) · Obesity · doi:10.1002/oby.70214 · Cited by 1
“Obesity is one of the factors that influences the plasma proteome in mice [25, 26] and humans [16, 17], and weight loss can also modify these profiles in humans [27–29].”
Al-Taweel, R., & Malki, A. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1813873 · Cited by 1
“Recent large-scale proteomic analysis of semaglutide therapy in individuals with overweight or obesity, with or without type 2 diabetes, demonstrated a distinct proteomic signature following treatment (26).”
Wangikar, P. P., Vinodkumar, K., Agarwal, K., Sunder, A. V., Sahasrabuddhe, D., Kulkarni, B., Kamath, M. S., Malhotra, N., & Kapoor, N. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102129 · Cited by 1
Adiposity and cancer: epidemiology, mechanisms and future perspectives
Watts, E. L., Gonzalez‐Feliciano, A. G., Gunter, M. J., Chatterjee, N., & Moore, S. C. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01529-5 · Cited by 4
“This score had lower levels of proteins that have been found to be elevated in women with breast cancer 153 .”
Ziegler, D., Kempler, P., Bala, C. G., Mankovsky, B., Schnell, O., Spallone, V., Stirban, A. O., & Tesfaye, S. H. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02241-w · Cited by 3
“…pain in the real-world proteomic profiles in the deCODE study were upregulated by semaglutide, while proteins upregulated with neuropathic pain in the deCODE study were downregulated by semaglutide, contributing to the concept of GLP-1RAs actions beyond weight loss and glucose lowering [35].”
Edvardsson, C. E., Adermark, L., Gottlieb, S., Alfreji, S., Emous, T. A., Gouda, Y., Thorsell, A., Vujičić, M., Aranäs, C., Benrick, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.26.672374 · Cited by 1
“Recent clinical research with semaglutide in obesity has identified similar proteomic changes in blood samples, including proteins linked to substance use disorders, such as histones (79).”
Dammer, E. B., Afshar, S., Bian, S., Seyfried, N. T., Levey, A. I., Fortea, J., & Johnson, E. C. B. (2026) · medRxiv · doi:10.64898/2026.02.14.26346321 · Cited by 1
Tangirala, S., Isaac, S., Gehad, Y., Roquefort, F., Gabrieli, P., Leong, A., Mercader, J. M., Sevilla-González, M. D. R., Baldini, F., Miller, G. W., et al. (2025) · medRxiv · doi:10.1101/2025.09.26.25336579
“We compared UKB-derived protein associations with those observed in the STEP 1 (obesity and non-T2D) and STEP 2 (T2D) semaglutide trials 16 , 29 .”
InfluentialYesavage, T. A. (2025) · Genetic Engineering & Biotechnology News · doi:10.1089/gen.45.10.16
Effects of obesity and weight loss interventions on cardiovascular diseases: A narrative review
Han, C., Hu, L., Song, L., & Guo, D. (2025) · Asian Heart Journal · doi:10.1097/ah9.0000000000000016
Jin, T., Meng, Y., Ren, L., & Wang, Y. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0032
EFEITOS TERAPÊUTICOS DOS AGONISTAS DO RECEPTOR DO GLP-1: UM ESTUDO DE REVISÃO
Gonçalves, F. M., Araújo, F. D. S., Barbosa, G. F., Presoto, C. L. Z., & Gardizani, T. P. (2025) · Revista Omnia Saúde · doi:10.69719/ros.v8.862
Landman, J. M., Highland, H. M., Perry, A., Howard, A. G., Sheng, Q., Lorenz, A., Bukowski, A., Zhao, S., Zhu, W., Zhang, X., et al. (2025) · medRxiv · doi:10.1101/2025.10.27.25338754 · Cited by 1
Individualized Medicine for Cardiovascular Disease: The curATime Consortium
Cate, V. T., & Wild, P. S. (2025) · Springer eBooks · doi:10.1007/978-3-031-93623-4_8
Han, M. H., Hwang, Y. S., Jin, D. H., & Kim, J. W. (2026) · Journal of Mechanics in Medicine and Biology · doi:10.1142/s0219519426300012
Khan, T., Ansarullah, A., George, J., Tomalka, J. A., Sékaly, R., Palucka, K., & Chaussabel, D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.22.701191
“As an external reference for semaglutide-responsive biology, we used serum proteomics from the STEP semaglutide versus placebo trials, which quantified ~6,400 circulating proteins using SomaScan technology (Maretty et al. 2025).”
InfluentialZhang, B., Kong, L., Wang, Y., He, W., Yang, M., Zhang, X., Chen, X., Zhang, Y., Liu, B., Bai, M., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00990
Torres‐Martos, Á., Michalopoulou, M., Jurado‐Fasoli, L., Jebb, S. A., Carter, J., de Carvalho, C. A., Aguilera, C. M., Astbury, N. M., & Piernas, C. (2026) · Research Square · doi:10.21203/rs.3.rs-8700326/v1
Leveraging Multiomic Signatures to Predict Body Composition
Devarakonda, S. L. S., Hughes, D. A., Rodriguez, C., Goncalves, M. D., & Heymsfield, S. B. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100626 · Cited by 2
“Although prediction algorithms cannot imply causality by themselves, evidence from randomized controlled trials and Mendelian randomization studies indicates that body composition traits causally influence interindividual variation in metabolites and proteins [44,45,50,65 – 72].”
Precision cardiovascular-kidney-metabolic care – ready for prime time? A fellow’s voice
Qian, F. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101669
“Precise molecular phenotyping ( “ -omics ” ) has also garnered significant interest both to refine clinical phenotyping as well as to assess treatment response [4,5].”
Chadwick, J., Carpenter, M., Budoff, M. J., Deo, R., Dubin, R. F., Greenland, P., Hinterberg, M., Malhotra, R., Miller, C. L., Rotter, J. I., et al. (2026) · medRxiv · doi:10.64898/2026.05.12.26353070
Liu, D., Lin, X., Xie, J., Chen, L., & Wang, N. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113329
Cardioprotective therapy in type 2 diabetes guided by a proteomic risk model: A randomized trial
Gill, R. D., Carpenter, M. A., Holstein, A., Garcia, A. R., Alkholder, A., Gupta, A., Singh, V., Quyyumi, A. A., Rasouli, N., Neeland, I. J., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101426 · Cited by 3
“…semaglutide, even after adjusting for weight loss and glycemic changes (associated with T2D), the circulating proteome showed modulation of lipid and inflammatory pathways, and CV-risk-related proteins; individuals with and without T2D taking semaglutide showed a reduction in RCVR risk scores [25].”
Rooney, M. R., Echouffo-Tcheugui, J. B., Chen, J., Walker, K. A., Ballantyne, C. M., Boerwinkle, E., Kelly, T. N., Ndumele, C. E., Pankow, J. S., Grams, M. E., et al. (2026) · Diabetes Care · doi:10.2337/dc26-0498
Applying immunity and metabolism to psychiatry: lost, or in translation?
Giorgi, R. D., Hahn, M. K., Cheliotis-James, T., Smith, E. C. C., Penninx, B. W. J. H., Pillinger, T., & Al‐Diwani, A. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10714 · Cited by 4
“38 These signatures overlap with disease proteomes, such as depression and substance misuse, generating rational repurposing hypotheses.”
Advances in proteomics research related to semaglutide: evidence from humans and animals
Jia, Q., Mu, H., Wang, Y., Gao, Z., & Gao, Z. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02989-y
“Collectively, these findings suggest that semaglutide is associated with systemic alterations in inflammation-related protein networks and circulating markers linked to extracellular matrix turnover [20].”
Lipska, D., Suvitaival, T., Kienle, S. M., von Scholten, B. J., Ripa, R. S., Zobel, E. H., Størling, J., Blond, M. B., Ahluwalia, T. S., Hansen, T. W., et al. (2026) · medRxiv · doi:10.64898/2026.07.22.26358565
Self-citationAnti-Obesity Medications in Longevity and Aesthetic Medicine
Bijoch, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15156026
“Crucially, several of these benefits appear, at least in part, before or out of proportion to weight loss, suggesting direct receptor-mediated tissue effects rather than purely the downstream consequences of reduced adiposity [4,21].”
Digestive hormones and their impact on bariatric and pharmacologic weight-loss therapies
Amoyel, M., Carette, C., Poghosyan, T., Beyec, J. L., & Gall, M. L. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag032
Guvatova, Z. G., Kobelyatskaya, A. A., Gorbunov, A., Pudova, E. A., & Moskalev, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177580
“SomaScan-based proteomic profiling was also used to characterize plasma protein changes following treatment with the GLP-1 receptor agonist semaglutide in individuals with obesity, drawing on STEP 1 and STEP 2 randomized clinical trial samples [118].”
He, Y., Gao, J., Liu, Y., Wu, S., Kuang, J., Chen, D., Xu, B., Zhang, M., & Fang, Q. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111163
Prospects for the use of new antidiabetic drugs in rheumatology
Nasonov, E. L., Shestakova, M. V., Kondratyeva, L. V., & Елисеев, М. С. (2026) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2026-315-334 · Cited by 1
Pavshintsev, V. V., Erbaeva, A. Z., Vatlin, A. A., & Mitkin, N. A. (2026) · Biomedicines · doi:10.3390/biomedicines14091987
“The analysis of samples from STEP 1 and STEP 2 trials showed that semaglutide downregulated multiple circulating inflammatory and immune response-related proteins independently of weight loss and glycemic improvement [7].”
Landman, J. M., Highland, H. M., Perry, A., Howard, A. G., Sheng, Q., Lorenz, A., Palmer, A. B., Zhao, S., Zhu, W., Zhang, X., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01589-7
“The proteomic data from STEP 1 can be found in the supplemental data from a previous study 15 (sheet ‘S2_tx_STEP1’, columns ‘effect_size’ and ‘qvalue’).”
InfluentialHuang, Y., Li, P.-Y., Liu, K.-W., Li, P., Chen, S.-C., Chen, J., Meyerowitz‐Katz, G., Huang, J.-Y., & Su, P. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261490985
Advances in weight-loss-independent cardiovascular protective mechanisms of GLP-1 receptor agonists
Ma, J., Feng, X., Xu, W., & Lyu, J. (2026) · Peptides · doi:10.1016/j.peptides.2026.171519
Semaglutide in Atrial Arrhythmias: State of the Art and Future Perspectives
Maggio, E., Trivigno, S., Mariani, M. V., Piro, A., Pierucci, N., Vernile, A., Vinciullo, S., Palombi, M., Vizza, C. D., & Lavalle, C. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16100506
“…inflammation, epicardial adiposity, and HF—rather than in exerting the direct ion-channel effects of a conventional antiarrhythmic drug [3,13,26,29–31, 42, Current randomised-trial meta-analyses suggest a reduction in reported AF events, while emerging observational studies indicate a…”
InfluentialDempster, N. J., Gade, F. S., Daly, C., Mbasu, R. J., Chen, L., Dong, J., Gangitano, E., Sgromo, B., Gillies, R. S., White, S. J., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156793
Preprocessing Large-Scale Proteomics Data
Sun, X., Ralser, M., & Messner, C. B. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5519-1_4
Metadata
- Authors
- Maretty, L., Gill, D., Simonsen, L., Soh, K., Zagkos, L., Galanakis, M., Sibbesen, J., Iglesias, M. T., Secher, A., Valkenborg, D., Purnell, J. Q., Knudsen, L. B., Tahrani, A. A., & Geybels, M.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Imperial College London (GB)
- Hasselt University (BE)
- Oregon Health & Science University (US)
- Corresponding author
- Tahrani, Abd A.
- ORCID
- Venue
- Nature Medicine
- Published
- 2025-01
- Volume
- 31
- Issue
- 1
- Pages
- 267-277
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11750704
- OpenAlex
- W4406051813
- Cited by
- 86
- References
- 69
- Citations by year
- 2026: 52 · 2025: 33
- FWCI
- 47.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 2 d)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
- Document Server@UHasselt (UHasselt) (submittedVersion, other-oa)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, obesity, type 2 diabetes, circulating proteome, serum proteins, pharmacological weight loss, glycemic control, lipid metabolism, inflammation, cardiovascular risk, drug repurposing
- MeSH terms
- Semaglutide, Adult, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Male, Middle Aged, Obesity, Weight Loss, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Proteome, Proteomics, Glucagon-Like Peptide 1, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.